Tirzepatide 10 and 15 mg versus semaglutide 2.4 mg in people with obesity or overweight with type 2 diabetes: An indirect treatment comparison
This analysis suggested greater reductions in bodyweight and HbA1c (%) levels associated with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg in people with obesity or overweight and T2D.
Authors
- Xiaotian Michelle Zhang (ORCID: https://orcid.org/0000-0002-4262-9128)
- Raleigh Malik (ORCID: https://orcid.org/0000-0002-2797-3545)
- W. Timothy Garvey (ORCID: https://orcid.org/0000-0003-0822-0860)
- Emily R. Hankosky (ORCID: https://orcid.org/0000-0001-9934-584X)
- Anna Niemeyer (ORCID: https://orcid.org/0000-0002-7166-212X)
- Fangyu Wang
- Julia Fraseur Brumm
- Xuanyao He
Institutions
- Eli Lilly (United States) (US)
- University of Alabama at Birmingham (US)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2025-05-05
- DOI
- https://doi.org/10.1111/dom.16401
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 9.06
Funders
- Eli Lilly and Company